Patents by Inventor Luc Van Hijfte

Luc Van Hijfte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of the interaction between MDM2 and P53
    Patent number: 8404683
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, X, Y, Q and Z have defined meanings.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: March 26, 2013
    Assignee: Janssen Pharmaceutical N.V.
    Inventors: Jean Ferand Armand Lacrampe, Christophe Meyer, Yannick Aimè Eddy Ligny, Imre Christian Francis Csoka, Luc Van Hijfte, Janine Arts, Bruno Schoentjes, Camille Georges Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert
  • Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and P53
    Patent number: 8377961
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, t, R1, R2, R3, R4, R5, R6, R7, Q, Y and Z have defined meanings.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: February 19, 2013
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Jean Fernand Armand Lacrampe, Christophe Meyer, Bruno Schoentjes, Alain Philippe Poncelet, Camille Georges Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert, Luc Van Hijfte
  • Inhibitors of the interaction between MDM2 and P53
    Patent number: 8232298
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R1, R2, A and Z have defined meanings.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: July 31, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Jean Fernand Armand Lacrampe, Christophe Meyer, Bruno Schoentjes, Delphine Yvonne Raymonde Lardeau, Alain Philippe Poncelet, Luc Van Hijfte
  • CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53
    Publication number: 20120071508
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, t, R1, R2, R3, R4, R5, R6, R7, Q, Y and Z have defined meanings.
    Type: Application
    Filed: November 30, 2011
    Publication date: March 22, 2012
    Inventors: Jean Fernand Armand Lacrampe, Christophe Meyer, Bruno Schoentjes, Alain Philippe Poncelet, Camille Georges Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert, Luc Van Hijfte
  • Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and p53
    Patent number: 8088795
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, t, R1, R2, R3, R4, R5, R6, R7, Q, Y and Z have defined meanings.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: January 3, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Jean Fernand Armand Lacrampe, Christophe Meyer, Bruno Schoentjes, Alain Philippe Poncelet, Camille Georges Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert, Luc Van Hijfte
  • Inhibitors of the Interaction Between MDM2 and P53
    Publication number: 20110053937
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, X, Y, Q and Z have defined meanings.
    Type: Application
    Filed: November 3, 2010
    Publication date: March 3, 2011
    Inventors: Jean Fernand Armand Lacrampe, Christophe Meyer, Yannick Aimé Eddy Ligny, Imre Christian Francis Csoka, Luc Van Hijfte, Janine Arts, Bruno Schoentjes, Camille Georges Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert
  • Inhibitors of the interaction between MDM2 and p53
    Patent number: 7834016
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, X, Y, Q and Z have defined meanings.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: November 16, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jean Fernand Armand Lacrampe, Christophe Meyer, Yannick Aimé Eddy Ligny, Imre Christian Francis Csoka, Luc Van Hijfte, Janine Arts, Bruno Schoentjes, Camille Georges Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert
  • Cosmetic and pharmaceutical compositions comprising compounds that display retinoid like activities
    Patent number: 7803966
    Abstract: This invention relates to novel compounds that display retinoid like activities, including HB-EGF (Heparin Binding Epidermal Growth Factor) release from keratinocytes, cell proliferation, and epidermal thickening without the irritation potentials, such as release of interleukin 8 and inhibition of terminal differentiation of keratinocytes. This invention also relates to the use of such a compound for both external and non-external applications.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: September 28, 2010
    Assignee: Johnson & Johnson Consumer France, S.A.S.
    Inventors: Thierry Oddos, Otto von Stetten, Luc van Hijfte
  • CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53
    Publication number: 20100168163
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, t, R1, R2, R3, R4, R5, R6, R7, Q, Y and Z have defined meanings.
    Type: Application
    Filed: March 19, 2007
    Publication date: July 1, 2010
    Inventors: Jean Fernand Armand Lacrampe, Christophe Meyer, Bruno Schoentjes, Alain Philippe Poncelet, Camille Georges Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert, Luc Van Hijfte
  • COSMETIC AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20090203654
    Abstract: This invention relates to novel compounds that display retinoid like activities, including HB-EGF (Heparin Binding Epidermal Growth Factor) release from keratinocytes, cell proliferation, and epidermal thickening without the irritation potentials, such as release of interleukin 8 and inhibition of terminal differentiation of keratinocytes. This invention also relates to the use of such a compound for both external and non-external applications.
    Type: Application
    Filed: December 16, 2008
    Publication date: August 13, 2009
    Inventors: Thierry Oddos, Otto von Stetten, Luc van Hijfte
  • INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53
    Publication number: 20090149493
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R1, R2, A and Z have defined meanings.
    Type: Application
    Filed: March 19, 2007
    Publication date: June 11, 2009
    Inventors: Jean Fernand Armand Lacrampe, Christophe Meyer, Bruno Schoentjes, Delphine Yvonne Raymonde Lardeau, Alain Philippe Poncelet, Luc Van Hijfte
  • Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors
    Patent number: 7482342
    Abstract: Compound corresponding to general formula (I): in which, R1 represents a hydrogen or halogen atom, an NH2, NHR2, NHCOR2, NO2, CN, CH2NH2 and CH2NHR2; or alternatively R1 represents an optionally substituted phenyl or an optionally substituted heteroaromatic group; Ar represents an optionally substituted phenyl group or an optionally substituted heteroaromatic group; n represents 0, 1, 2 or 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate. Application in therapy.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: January 27, 2009
    Assignee: sanofi-aventis
    Inventors: Hugues D'Orchymont, Luc Van Hijfte, Andre Zimmermann
  • Inhibitors of the Interaction Between Mdm2 and P53
    Publication number: 20080039472
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, X, Y, Q and Z have defined meanings.
    Type: Application
    Filed: September 16, 2005
    Publication date: February 14, 2008
    Applicant: JANSSEN PHARMACEUTICA N.V.
    Inventors: Jean Lacrampe, Christophe Meyer, Yannick Ligny, Imre Csoka, Luc Van Hijfte, Janine Arts, Bruno Schoentjes, Camille Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert
  • Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors
    Publication number: 20060004000
    Abstract: Compound corresponding to general formula (I): in which, R1 represents a hydrogen or halogen atom, an NH2, NHR2, NHCOR2, NO2, CN, CH2NH2 and CH2NHR2; or alternatively R1 represents an optionally substituted phenyl or an optionally substituted heteroaromatic group; Ar represents an optionally substituted phenyl group or an optionally substituted heteroaromatic group; n represents 0, 1, 2 or 3; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate. Application in therapy.
    Type: Application
    Filed: April 1, 2005
    Publication date: January 5, 2006
    Applicant: SANOFI-AVENTIS
    Inventors: Hugues D'Orchymont, Luc Van Hijfte, Andre Zimmermann
  • Esters of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidi nemethanol
    Patent number: 6063793
    Abstract: The present invention is directed to esters of (+)-.alpha.-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol, pharmaceutical formulations, methods of making and methods of using these esters. These compounds antagonize the effects of serotonin at the 5HT.sub.2A receptor and are useful in treating various conditions such as, for example, psychoses such as schizophrenia.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: May 16, 2000
    Assignee: Hoechst Marion Roussel, Inc.
    Inventors: Albert A. Carr, Raymond W. Kosley, Jr., Luc Van Hijfte
  • Esters of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
    Patent number: 6028083
    Abstract: The present invention is directed to esters of (+)-.alpha.-(2,3 Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol, pharmaceutical formulations, methods of making and methods of using these esters. These compounds antagonize the effects of serotonin at the 5HT.sub.2A receptor and are useful in treating various conditions such as, for example, psychoses such as schizophrenia.
    Type: Grant
    Filed: July 25, 1997
    Date of Patent: February 22, 2000
    Assignee: Hoechst Marion Roussel, Inc.
    Inventors: Albert A. Carr, Raymond W. Kosley, Jr., Luc Van Hijfte
  • 5H-Dibenzo (A,D) cycloheptenes as muscarinic receptor antagonists
    Patent number: 5508280
    Abstract: This invention relates to novel derivatives of 5H-dibenzo (a,d)cycloheptenes, to the processes for their preparation, to their muscarinic receptor antagonist properties and to their end-use application for treating Parkinson's Disease, tardive dyskinesia, and motion sickness.
    Type: Grant
    Filed: January 30, 1995
    Date of Patent: April 16, 1996
    Assignee: Merrell Pharmaceuticals, Inc.
    Inventors: Marcel Hibert, Luc Van Hijfte, Mary Richards, Paul Moser
  • Novel process and intermediates
    Patent number: 5055592
    Abstract: This invention relates to the novel processes for the preparation of a 16-methoxy-16-methyl prostaglandin E.sub.1 derivative and to the novel intermediates useful therefor.
    Type: Grant
    Filed: January 30, 1990
    Date of Patent: October 8, 1991
    Assignee: Merrell Dow Pharmaceuticals
    Inventors: Michael Kolb, Luc Van Hijfte